Lacosamid Glenmark

Lacosamide, the active ingredient in Lacosamid, is an Anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency when used as adjunct therapy.

GNH USA supplies Lacosamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: adjunctive therapy that reduces seizure frequency in epilepsy patients. - Focal epilepsy: improves seizure control when added to existing antiepileptic regimens. - Epilepsy (adjunctive therapy): contributes to overall seizure management as part of combination treatment.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild gastrointestinal upset. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate cranial pain. - Somnolence: tendency to feel sleepy. - Diplopia: occasional double vision.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing heart disease. - Suicidal ideation: emergence of thoughts of self‑harm. - Severe hepatic injury: marked liver enzyme elevation or failure. - Anaphylaxis: rare allergic reaction with respiratory compromise.

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: monitor renal function and adjust dose if needed. - Hepatic impairment: use with caution and observe liver enzymes. - Pregnancy: risk unknown; prescribe only if benefits outweigh potential fetal risks. - Concomitant antiepileptics: assess for additive CNS depression or altered plasma levels. - Driving and operating machinery: advise patients about possible dizziness or somnolence. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Lacosamide exposure. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce therapeutic levels. - Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: Lacosamide may lower hormonal efficacy. - Certain antidepressants (e.g., SSRIs): potential for serotonin syndrome. - Alcohol: may enhance central nervous system depression.